AbbVie's Migraine Drug Qulipta Achieves Key Clinical Milestone
AbbVie, a leading pharmaceutical company known for its work in immunology and migraine treatments, recently announced positive results from a Phase 3 clinical trial of its drug Qulipta. The study showed that the medication significantly reduced migraine days during the perimenstrual period compared to placebo, meeting both primary and secondary endpoints without new safety concerns. Qulipta is already approved for preventive treatment in migraines but now appears poised for a label expansion specifically targeting menstrual migraines—a niche with no currently approved treatments. AbbVie estimates that this could open the drug up to over nine million adult patients in the U.S., though actual market penetration will depend on factors like insurance coverage and physician adoption. While Qulipta's success is notable, it remains a smaller part of AbbVie’s portfolio compared to its immunology drugs Skyrizi and Rinvoq. In Q2 2024, Qulipta generated $350 million in sales with analysts projecting peak potential above $2 billion.
Tickers: $ABBV
Topics: AbbVie clinical trial results migraine treatment Qulipta